Pharmacological investigation of NOP-related ligands as analgesics without abuse liability

ACS Symposium Series

Volumn 1131, Issue , 2013, Pages 393-416

  Sukhtankar, Devki ^a   Ko, Mei Chuan ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATION ANALYSIS; DRUG INTERACTIONS; DRUG PRODUCTS; HEALTH; MAMMALS;

ANALGESIC DRUGS; ANTINOCICEPTION; ANTINOCICEPTIVE EFFECT; OPIOID ANALGESICS; REINFORCING EFFECTS; RESPIRATORY DEPRESSION; SYSTEMIC ADMINISTRATION; THERAPEUTIC POTENTIALS;

LIGANDS;

EID: 84905499338     PISSN: 00976156     EISSN: 19475918     Source Type: Book Series    
DOI: 10.1021/bk-2013-1131.ch018     Document Type: Conference Paper

References (133)

1. Zollner, C.; Stein, C. Opioids. Handb. Exp. Pharmacol. 2007, 31-63.
2. Duthie, D. J.; Nimmo, W. S. Adverse effects of opioid analgesic drugs. Br. J. Anaesth. 1987, 59, 61-77.
3. Cicero, T. J.; Surratt, H.; Inciardi, J. A.; Munoz, A. Relationship between therapeutic use and abuse of opioid analgesics in rural, suburban, and urban locations in the United States. Pharmacoepidemiol. Drug Saf. 2007, 16, 827-840.
4. Katz, N. P.; Adams, E. H.; Benneyan, J. C.; Birnbaum, H. G.; Budman, S. H.; Buzzeo, R. W.; Carr, D. B.; Cicero, T. J.; Gourlay, D.; Inciardi, J. A.; Joranson, D. E.; Kesslick, J.; Lande, S. D. Foundations of opioid risk management. Clin. J. Pain 2007, 23, 103-118.
5. Cousins, M. J.; Mather, L. E. Intrathecal and epidural administration of opioids. Anesthesiology 1984, 61, 276-310.
6. Ballantyne, J. C.; Loach, A. B.; Carr, D. B. Itching after epidural and spinal opiates. Pain 1988, 33, 149-160.
7. DeBalli, P.; Breen, T. W. Intrathecal opioids for combined spinal-epidural analgesia during labour. CNS Drugs 2003, 17, 889-904.
8. Christo, P. J.; Mazloomdoost, D. Cancer pain and analgesia. Ann. N. Y. Acad. Sci. 2008, 1138, 278-298.
9. Puntillo, K.; Casella, V.; Reid, M. Opioid and benzodiazepine tolerance and dependence: application of theory to critical care practice. Heart Lung 1997, 26, 317-324.
10. Varney, S. M.; Bebarta, V. S. Opioid-induced hyperalgesia-worsening pain in opioid-dependent patients. Am. J. Emerg. Med. 2012.
11. Martin, C. M. When medications make pain worse: opioid-induced hyperalgesia. Consult. Pharm. 2011, 26, 530-542.
12. Silverman, S. M. Opioid induced hyperalgesia: clinical implications for the pain practitioner. Pain Physician 2009, 12, 679-684.
13. Bunzow, J. R.; Saez, C.; Mortrud, M.; Bouvier, C.; Williams, J. T.; Low, M.; Grandy, D. K. Molecular cloning and tissue distribution of a putative member of the rat opioid receptor gene family that is not a mu, delta or kappa opioid receptor type. FEBS Lett. 1994, 347, 284-288.
14. Mollereau, C.; Parmentier, M.; Mailleux, P.; Butour, J. L.; Moisand, C.; Chalon, P.; Caput, D.; Vassart, G.; Meunier, J. C. ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization. FEBS Lett. 1994, 341, 33-38.
15. Wick, M. J.; Minnerath, S. R.; Lin, X.; Elde, R.; Law, P. Y.; Loh, H. H. Isolation of a novel cDNA encoding a putative membrane receptor with high homology to the cloned mu, delta, and kappa opioid receptors. Brain Res. Mol. Brain Res. 1994, 27, 37-44.
16. Meunier, J. C.; Mollereau, C.; Toll, L.; Suaudeau, C.; Moisand, C.; Alvinerie, P.; Butour, J. L.; Guillemot, J. C.; Ferrara, P.; Monsarrat, B.; et al. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature 1995, 377, 532-535.
17. Reinscheid, R. K.; Nothacker, H. P.; Bourson, A.; Ardati, A.; Henningsen, R. A.; Bunzow, J. R.; Grandy, D. K.; Langen, H.; Monsma, F. J., Jr.; Civelli, O. Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor. Science 1995, 270, 792-794.
18. Thompson, A. A.; Liu, W.; Chun, E.; Katritch, V.; Wu, H.; Vardy, E.; Huang, X. P.; Trapella, C.; Guerrini, R.; Calo, G.; Roth, B. L.; Cherezov, V.; Stevens, R. C. Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic. Nature 2012, 485, 395-399.
19. Henderson, G.; McKnight, A. T. The orphan opioid receptor and its endogenous ligand-nociceptin/orphanin FQ. Trends Pharmacol. Sci. 1997, 18, 293-300.
20. Darland, T.; Heinricher, M. M.; Grandy, D. K. Orphanin FQ/nociceptin: a role in pain and analgesia, but so much more. Trends Neurosci. 1998, 21, 215-221.
21. Darland, T.; Grandy, D. K. The orphanin FQ system: an emerging target for the management of pain? Br. J. Anaesth. 1998, 81, 29-37.
22. Mollereau, C.; Mouledous, L. Tissue distribution of the opioid receptor-like (ORL1) receptor. Peptides 2000, 21, 907-917.
23. Devine, D. P.; Reinscheid, R. K.; Monsma, F. J., Jr.; Civelli, O.; Akil, H. The novel neuropeptide orphanin FQ fails to produce conditioned place preference or aversion. Brain Res. 1996, 727, 225-229.
24. Le Pen, G.; Wichmann, J.; Moreau, J. L.; Jenck, F. The orphanin receptor agonist RO 64-6198 does not induce place conditioning in rats. Neuroreport 2002, 13, 451-454.
25. Rutten, K.; De Vry, J.; Bruckmann, W.; Tzschentke, T. M. Effects of the NOP receptor agonist Ro65-6570 on the acquisition of opiate- and psychostimulant-induced conditioned place preference in rats. Eur. J. Pharmacol. 2010, 645, 119-126.
26. Wu, X. J.; Zong, W.; Sun, Y. M.; Hu, X. T.; Ma, Y. Y.; Wang, J. H. [Morphine addiction in non-human primates using rhesus monkeys]. Dongwuxue Yanjiu 2012, 33, 89-91.
27. Watanabe, S. Social factors in conditioned place preference with morphine in mice. Pharmacol. Biochem. Behav. 2012, 103, 440-443.
28. Schnur, P.; Morrell, J. Morphine conditioned place preference in the hamster. Pharmacol. Biochem. Behav. 1990, 37, 383-385.
29. Nielsen, D. A.; Kreek, M. J. Common and specific liability to addiction: approaches to association studies of opioid addiction. Drug Alcohol Depend. 2012, 123 (Suppl 1), S33-41.
30. Stowe, G. N.; Schlosburg, J. E.; Vendruscolo, L. F.; Edwards, S.; Misra, K. K.; Schulteis, G.; Zakhari, J. S.; Koob, G. F.; Janda, K. D. Developing a vaccine against multiple psychoactive targets: a case study of heroin. CNS Neurol. Disord. Drug Targets 2011, 10, 865-875.
31. O'Connor, E. C.; Mead, A. N. Tramadol acts as a weak reinforcer in the rat self-administration model, consistent with its low abuse liability in humans. Pharmacol. Biochem. Behav. 2010, 96, 279-286.
32. Winger, G.; Galuska, C. M.; Hursh, S. R.; Woods, J. H. Relative reinforcing effects of cocaine, remifentanil, and their combination in rhesus monkeys. J. Pharmacol. Exp. Ther. 2006, 318, 223-229.
33. Weeks, J. R.; Collins, R. J. Self-administration of morphine in the rat: relative influence of fixed ratio and time-out. Pharmacol. Biochem. Behav. 1978, 9, 703-704.
34. Baylon, G. J.; Kaplan, H. L.; Somer, G.; Busto, U. E.; Sellers, E. M. Comparative abuse liability of intravenously administered remifentanil and fentanyl. J. Clin. Psychopharmacol. 2000, 20, 597-606.
35. Webster, L. R.; Johnson, F. K.; Stauffer, J.; Setnik, B.; Ciric, S. Impact of intravenous naltrexone on intravenous morphine-induced high, drug liking, and euphoric effects in experienced, nondependent male opioid users. Drugs R&D 2011, 11, 259-275.
36. Sukhtankar, D. S.; Lagorio, C. H.; Ko, M. C. Examining the reinforcing properties of NOP receptor agonist SCH221510 and its role in attenuating mu-receptor mediated reinforcement in a rat self-administration assay. In Experimental. Biology 2013 - Abstract; 2013.
37. Ko, M. C.; Woods, J. H.; Fantegrossi, W. E.; Galuska, C. M.; Wichmann, J.; Prinssen, E. P. Behavioral effects of a synthetic agonist selective for nociceptin/orphanin FQ peptide receptors in monkeys. Neuropsychopharmacology 2009, 34, 2088-2096.
38. Di Giannuario, A.; Pieretti, S. Nociceptin differentially affects morphineinduced dopamine release from the nucleus accumbens and nucleus caudate in rats. Peptides 2000, 21, 1125-1130.
39. Lutfy, K.; Hossain, S. M.; Khaliq, I.; Maidment, N. T. Orphanin FQ/nociceptin attenuates the development of morphine tolerance in rats. Br. J. Pharmacol. 2001, 134, 529-534.
40. Murphy, N. P.; Maidment, N. T. Orphanin FQ/nociceptin modulation of mesolimbic dopamine transmission determined by microdialysis. J. Neurochem. 1999, 73, 179-186.
41. Ciccocioppo, R.; Angeletti, S.; Panocka, I.; Massi, M. Nociceptin/orphanin FQ and drugs of abuse. Peptides 2000, 21, 1071-1080.
42. Murphy, N. P.; Lee, Y.; Maidment, N. T. Orphanin FQ/nociceptin blocks acquisition of morphine place preference. Brain Res. 1999, 832, 168-170.
43. Sakoori, K.; Murphy, N. P. Central administration of nociceptin/orphanin FQ blocks the acquisition of conditioned place preference to morphine and cocaine, but not conditioned place aversion to naloxone in mice. Psychopharmacology (Berl.) 2004, 172, 129-136.
44. Shoblock, J. R.; Wichmann, J.; Maidment, N. T. The effect of a systemically active ORL-1 agonist, Ro 64-6198, on the acquisition, expression, extinction, and reinstatement of morphine conditioned place preference. Neuropharmacology 2005, 49, 439-446.
45. Kuzmin, A.; Sandin, J.; Terenius, L.; Ogren, S. O. Acquisition, expression, and reinstatement of ethanol-induced conditioned place preference in mice: effects of opioid receptor-like 1 receptor agonists and naloxone. J. Pharmacol. Exp. Ther. 2003, 304, 310-318.
46. Kuzmin, A.; Kreek, M. J.; Bakalkin, G.; Liljequist, S. The nociceptin/ orphanin FQ receptor agonist Ro 64-6198 reduces alcohol self-administration and prevents relapse-like alcohol drinking. Neuropsychopharmacology 2007, 32, 902-910.
47. Rutten, K.; De Vry, J.; Bruckmann, W.; Tzschentke, T. M. Pharmacological blockade or genetic knockout of the NOP receptor potentiates the rewarding effect of morphine in rats. Drug Alcohol Depend. 2011, 114, 253-256.
48. Marquez, P.; Nguyen, A. T.; Hamid, A.; Lutfy, K. The endogenous OFQ/ N/ORL-1 receptor system regulates the rewarding effects of acute cocaine. Neuropharmacology 2008, 54, 564-568.
49. Podlesnik, C. A.; Ko, M. C.; Winger, G.; Wichmann, J.; Prinssen, E. P.; Woods, J. H. The effects of nociceptin/orphanin FQ receptor agonist Ro 64- 6198 and diazepam on antinociception and remifentanil self-administration in rhesus monkeys. Psychopharmacology (Berl.) 2011, 213, 53-60.
50. Robinson, S. E. Buprenorphine: an analgesic with an expanding role in the treatment of opioid addiction. CNS Drug Rev. 2002, 8, 377-390.
51. Manlandro, J. J., Jr. Buprenorphine for office-based treatment of patients with opioid addiction. J. Am. Osteopath. Assoc. 2005, 105, S8-13.
52. Cicero, T. J.; Surratt, H. L.; Inciardi, J. Use and misuse of buprenorphine in the management of opioid addiction. J. Opioid Manage. 2007, 3, 302-308.
53. Malcolm, R.; O'Neil, P. M.; Von, J. M.; Dickerson, P. C. Naltrexone and dysphoria: a double-blind placebo controlled trial. Biol. Psychiatry 1987, 22, 710-716.
54. Crowley, T. J.; Wagner, J. E.; Zerbe, G.; Macdonald, M. Naltrexone-induced dysphoria in former opioid addicts. Am. J. Psychiatry 1985, 142, 1081-1084.
55. Kosten, T. R.; Kleber, H. D. Strategies to improve compliance with narcotic antagonists. Am. J. Drug Alcohol Abuse 1984, 10, 249-266.
56. Koster, A.; Montkowski, A.; Schulz, S.; Stube, E. M.; Knaudt, K.; Jenck, F.; Moreau, J. L.; Nothacker, H. P.; Civelli, O.; Reinscheid, R. K. Targeted disruption of the orphanin FQ/nociceptin gene increases stress susceptibility and impairs stress adaptation in mice. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 10444-10449.
57. Jenck, F.; Wichmann, J.; Dautzenberg, F. M.; Moreau, J. L.; Ouagazzal, A. M.; Martin, J. R.; Lundstrom, K.; Cesura, A. M.; Poli, S. M.; Roever, S.; Kolczewski, S.; Adam, G.; Kilpatrick, G. A synthetic agonist at the orphanin FQ/nociceptin receptor ORL1: anxiolytic profile in the rat. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 4938-4943.
58. Mogil, J. S.; Grisel, J. E.; Zhangs, G.; Belknap, J. K.; Grandy, D. K. Functional antagonism of mu-, delta- and kappa-opioid antinociception by orphanin FQ. Neurosci. Lett. 1996, 214, 131-134.
59. Tian, J. H.; Xu, W.; Fang, Y.; Mogil, J. S.; Grisel, J. E.; Grandy, D. K.; Han, J. S. Bidirectional modulatory effect of orphanin FQ on morphine-induced analgesia: antagonism in brain and potentiation in spinal cord of the rat. Br. J. Pharmacol. 1997, 120, 676-680.
60. Xu, X. J.; Hao, J. X.; Wiesenfeld-Hallin, Z. Nociceptin or antinociceptin: potent spinal antinociceptive effect of orphanin FQ/nociceptin in the rat. Neuroreport 1996, 7, 2092-2094.
61. Inoue, M.; Shimohira, I.; Yoshida, A.; Zimmer, A.; Takeshima, H.; Sakurada, T.; Ueda, H. Dose-related opposite modulation by nociceptin/ orphanin FQ of substance P nociception in the nociceptors and spinal cord. J. Pharmacol. Exp. Ther. 1999, 291, 308-313.
62. Hu, E.; Calo, G.; Guerrini, R.; Ko, M. C. Long-lasting antinociceptive spinal effects in primates of the novel nociceptin/orphanin FQ receptor agonist UFP-112. Pain 2010, 148, 107-113.
63. Ko, M. C.; Naughton, N. N. Antinociceptive effects of nociceptin/orphanin FQ administered intrathecally in monkeys. J. Pain 2009, 10, 509-516.
64. Wang, J. K.; Nauss, L. A.; Thomas, J. E. Pain relief by intrathecally applied morphine in man. Anesthesiology 1979, 50, 149-151.
65. Zech, D. F.; Grond, S.; Lynch, J.; Hertel, D.; Lehmann, K. A. Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study. Pain 1995, 63, 65-76.
66. Hanks, G. W.; Conno, F.; Cherny, N.; Hanna, M.; Kalso, E.; McQuay, H. J.; Mercadante, S.; Meynadier, J.; Poulain, P.; Ripamonti, C.; Radbruch, L.; Casas, J. R.; Sawe, J.; Twycross, R. G.; Ventafridda, V. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br. J. Cancer 2001, 84, 587-593.
67. Mercadante, S. Intrathecal morphine and bupivacaine in advanced cancer pain patients implanted at home. J. Pain Symptom Manage. 1994, 9, 201-207.
68. Hassenbusch, S. J.; Stanton-Hicks, M.; Covington, E. C.; Walsh, J. G.; Guthrey, D. S. Long-term intraspinal infusions of opioids in the treatment of neuropathic pain. J. Pain Symptom Manage. 1995, 10, 527-543.
69. Smitt, P. S.; Tsafka, A.; Teng-van de Zande, F.; van der Holt, R.; Elswijk-de Vries, I.; Elfrink, E.; van den Bent, M. J.; Vecht, C. J. Outcome and complications of epidural analgesia in patients with chronic cancer pain. Cancer 1998, 83, 2015-2022.
70. Arner, S.; Meyerson, B. A. Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain 1988, 33, 11-23.
71. Portenoy, R. K.; Foley, K. M.; Inturrisi, C. E. The nature of opioid responsiveness and its implications for neuropathic pain: new hypotheses derived from studies of opioid infusions. Pain 1990, 43, 273-286.
72. Devulder, J. Hyperalgesia induced by high-dose intrathecal sufentanil in neuropathic pain. J. Neurosurg. Anesthesiol. 1997, 9, 146-148.
73. Duarte, R. V.; Raphael, J. H.; Haque, M. S.; Southall, J. L.; Ashford, R. L. A predictive model for intrathecal opioid dose escalation for chronic non-cancer pain. Pain Physician 2012, 15, 363-369.
74. Ventafridda, V.; Spoldi, E.; Caraceni, A.; De Conno, F. Intraspinal morphine for cancer pain. Acta. Anaesthesiol. Scand. Suppl. 1987, 85, 47-53.
75. Gupta, H.; Verma, D.; Ahuja, R. K.; Srivastava, D. N.; Wadhwa, S.; Ray, S. B. Intrathecal co-administration of morphine and nimodipine produces higher antinociceptive effect by synergistic interaction as evident by injecting different doses of each drug in rats. Eur. J. Pharmacol. 2007, 561, 46-53.
76. Ouyang, H.; Bai, X.; Huang, W.; Chen, D.; Dohi, S.; Zeng, W. The antinociceptive activity of intrathecally administered amiloride and its interactions with morphine and clonidine in rats. J. Pain 2012, 13, 41-48.
77. Zhao, C.; Tall, J. M.; Meyer, R. A.; Raja, S. N. Antiallodynic effects of systemic and intrathecal morphine in the spared nerve injury model of neuropathic pain in rats. Anesthesiology 2004, 100, 905-911.
78. Nielsen, C. K.; Lewis, R. J.; Alewood, D.; Drinkwater, R.; Palant, E.; Patterson, M.; Yaksh, T. L.; McCumber, D.; Smith, M. T. Anti-allodynic efficacy of the chi-conopeptide, Xen2174, in rats with neuropathic pain. Pain 2005, 118, 112-124.
79. Lee, B. S.; Jun, I. G.; Kim, S. H.; Park, J. Y. Interaction of morphine and selective serotonin receptor inhibitors in rats experiencing inflammatory pain. J. Korean Med. Sci. 2012, 27, 430-436.
80. Zhao, Y. L.; Chen, S. R.; Chen, H.; Pan, H. L. Chronic opioid potentiates presynaptic but impairs postsynaptic N-methyl-D-aspartic acid receptor activity in spinal cords: implications for opioid hyperalgesia and tolerance. J. Biol. Chem. 2012, 287, 25073-25085.
81. Mattioli, G.; Guida, E.; Rossi, V.; Podesta, E.; Jasonni, V.; Ghiggeri, G. M. Intraureteral Injection of NASHA/Dx Gel Under Direct Ureteroscopic Visualization for the Treatment of Primary High-Grade Vesicoureteral Reflux. J. Laparoendosc. Adv. Surg. Tech. A. 2012, 22, 844-847.
82. Johnston, I. N.; Milligan, E. D.; Wieseler-Frank, J.; Frank, M. G.; Zapata, V.; Campisi, J.; Langer, S.; Martin, D.; Green, P.; Fleshner, M.; Leinwand, L.; Maier, S. F.; Watkins, L. R. A role for proinflammatory cytokines and fractalkine in analgesia, tolerance, and subsequent pain facilitation induced by chronic intrathecal morphine. J. Neurosci. 2004, 24, 7353-7365.
83. Mao, J.; Price, D. D.; Mayer, D. J. Thermal hyperalgesia in association with the development of morphine tolerance in rats: roles of excitatory amino acid receptors and protein kinase C. J. Neurosci. 1994, 14, 2301-2312.
84. Liang, D. Y.; Li, X.; Clark, J. D. 5-hydroxytryptamine type 3 receptor modulates opioid-induced hyperalgesia and tolerance in mice. Anesthesiology 2011, 114, 1180-1189.
85. Yaksh, T. L. In vivo studies on spinal opiate receptor systems mediating antinociception. I. Mu and delta receptor profiles in the primate. J. Pharmacol. Exp. Ther. 1983, 226, 303-316.
86. Ko, M. C.; Naughton, N. N. An experimental itch model in monkeys: characterization of intrathecal morphine-induced scratching and antinociception. Anesthesiology 2000, 92, 795-805.
87. Chaney, M. A. Side effects of intrathecal and epidural opioids. Can. J. Anaesth. 1995, 42, 891-903.
88. Kam, P. C.; Tan, K. H. Pruritus-itching for a cause and relief? Anaesthesia 1996, 51, 1133-1138.
89. Bertorelli, R.; Bastia, E.; Citterio, F.; Corradini, L.; Forlani, A.; Ongini, E. Lack of the nociceptin receptor does not affect acute or chronic nociception in mice. Peptides 2002, 23, 1589-1596.
90. Yamamoto, T.; Nozaki-Taguchi, N.; Kimura, S. Analgesic effect of intrathecally administered nociceptin, an opioid receptor-like1 receptor agonist, in the rat formalin test. Neuroscience 1997, 81, 249-254.
91. Yamamoto, T.; Nozaki-Taguchi, N.; Kimura, S. Effects of intrathecally administered nociceptin, an opioid receptor-like1 (ORL1) receptor agonist, on the thermal hyperalgesia induced by carageenan injection into the rat paw. Brain Res. 1997, 754, 329-332.
92. Erb, K.; Liebel, J. T.; Tegeder, I.; Zeilhofer, H. U.; Brune, K.; Geisslinger, G. Spinally delivered nociceptin/orphanin FQ reduces flinching behaviour in the rat formalin test. Neuroreport 1997, 8, 1967-1970.
93. Yamamoto, T.; Nozaki-Taguchi, N.; Kimura, S. Effects of intrathecally administered nociceptin, an opioid receptor-like1 (ORL1) receptor agonist, on the thermal hyperalgesia induced by unilateral constriction injury to the sciatic nerve in the rat. Neurosci. Lett. 1997, 224, 107-110.
94. Corradini, L.; Briscini, L.; Ongini, E.; Bertorelli, R. The putative OP(4) antagonist, [Nphe(1)]nociceptin(1-13)NH(2), prevents the effects of nociceptin in neuropathic rats. Brain Res. 2001, 905, 127-133.
95. Hao, J. X.; Xu, I. S.; Wiesenfeld-Hallin, Z.; Xu, X. J. Anti-hyperalgesic and anti-allodynic effects of intrathecal nociceptin/orphanin FQ in rats after spinal cord injury, peripheral nerve injury and inflammation. Pain 1998, 76, 385-393.
96. Rizzi, A.; Spagnolo, B.; Wainford, R. D.; Fischetti, C.; Guerrini, R.; Marzola, G.; Baldisserotto, A.; Salvadori, S.; Regoli, D.; Kapusta, D. R.; Calo, G. In vitro and in vivo studies on UFP-112, a novel potent and long lasting agonist selective for the nociceptin/orphanin FQ receptor. Peptides 2007, 28, 1240-1251.
97. Calo, G.; Rizzi, A.; Cifani, C.; Micioni Di Bonaventura, M. V.; Regoli, D.; Massi, M.; Salvadori, S.; Lambert, D. G.; Guerrini, R. UFP-112 a potent and long-lasting agonist selective for the Nociceptin/Orphanin FQ receptor. CNS Neurosci. Ther. 2011, 17, 178-198.
98. Obara, I.; Przewlocki, R.; Przewlocka, B. Spinal and local peripheral antiallodynic activity of Ro64-6198 in neuropathic pain in the rat. Pain 2005, 116, 17-25.
99. Mika, J.; Schafer, M. K.; Obara, I.; Weihe, E.; Przewlocka, B. Morphine and endomorphin-1 differently influence pronociceptin/orphanin FQ system in neuropathic rats. Pharmacol. Biochem. Behav. 2004, 78, 171-178.
100. Briscini, L.; Corradini, L.; Ongini, E.; Bertorelli, R. Up-regulation of ORL-1 receptors in spinal tissue of allodynic rats after sciatic nerve injury. Eur. J. Pharmacol. 2002, 447, 59-65.
101. Ma, F.; Xie, H.; Dong, Z. Q.; Wang, Y. Q.; Wu, G. C. Effects of electroacupuncture on orphanin FQ immunoreactivity and preproorphanin FQ mRNA in nucleus of raphe magnus in the neuropathic pain rats. Brain Res. Bull. 2004, 63, 509-513.
102. Jia, Y.; Linden, D. R.; Serie, J. R.; Seybold, V. S. Nociceptin/orphanin FQ binding increases in superficial laminae of the rat spinal cord during persistent peripheral inflammation. Neurosci. Lett. 1998, 250, 21-24.
103. Ko, M. C.; Wei, H.; Woods, J. H.; Kennedy, R. T. Effects of intrathecally administered nociceptin/orphanin FQ in monkeys: behavioral and mass spectrometric studies. J. Pharmacol. Exp. Ther. 2006, 318, 1257-1264.
104. Knotkova, H.; Pappagallo, M.; Szallasi, A. Capsaicin (TRPV1 Agonist) therapy for pain relief: farewell or revival? Clin. J. Pain 2008, 24, 142-154.
105. Szallasi, A.; Cortright, D. N.; Blum, C. A.; Eid, S. R. The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept. Nat. Rev. Drug Discov. 2007, 6, 357-372.
106. Butelman, E. R.; Harris, T. J.; Kreek, M. J. Antiallodynic effects of loperamide and fentanyl against topical capsaicin-induced allodynia in unanesthetized primates. J. Pharmacol. Exp. Ther. 2004, 311, 155-163.
107. Eisenach, J. C.; Hood, D. D.; Curry, R.; Tong, C. Alfentanil, but not amitriptyline, reduces pain, hyperalgesia, and allodynia from intradermal injection of capsaicin in humans. Anesthesiology 1997, 86, 1279-1287.
108. Park, K. M.; Max, M. B.; Robinovitz, E.; Gracely, R. H.; Bennett, G. J. Effects of intravenous ketamine, alfentanil, or placebo on pain, pinprick hyperalgesia, and allodynia produced by intradermal capsaicin in human subjects. Pain 1995, 63, 163-172.
109. Reiss, D.; Wichmann, J.; Tekeshima, H.; Kieffer, B. L.; Ouagazzal, A. M. Effects of nociceptin/orphanin FQ receptor (NOP) agonist, Ro64-6198, on reactivity to acute pain in mice: comparison to morphine. Eur. J. Pharmacol. 2008, 579, 141-148.
110. Khroyan, T. V.; Polgar, W. E.; Orduna, J.; Zaveri, N. T.; Judd, A. K.; Tuttle, D. J.; Sanchez, A.; Toll, L. Anti-nociceptive and anti-allodynic effects of a high affinity NOP hexapeptide [Ac-RY(3-Cl)YRWR-NH2] (Syn 1020) in rodents. Eur. J. Pharmacol. 2007, 560, 29-35.
111. Wladischkin, K. A.; Dysko, R. C.; Collins, G. T.; Ko, Y. A.; Winger, G.; Ko, M. C. Pharmacological characterization of NOP receptor agonists as abuse-free and constipation-free analgesics in monkeys. FASEB J. 2012, 26.
112. Bridge, K. E.; Wainwright, A.; Reilly, K.; Oliver, K. R. Autoradiographic localization of (125)i[Tyr(14)] nociceptin/orphanin FQ binding sites in macaque primate CNS. Neuroscience 2003, 118, 513-523.
113. Berthele, A.; Platzer, S.; Dworzak, D.; Schadrack, J.; Mahal, B.; Buttner, A.; Assmus, H. P.; Wurster, K.; Zieglgansberger, W.; Conrad, B.; Tolle, T. R. [3H]-nociceptin ligand-binding and nociceptin opioid receptor mrna expression in the human brain. Neuroscience 2003, 121, 629-640.
114. Foddi, M. C.; Mennini, T. [125I][Tyr14]Orphanin binding to rat brain: evidence for labelling the opioid-receptor-like 1 (ORL1). Neurosci. Lett. 1997, 230, 105-108.
115. Ikeda, K.; Watanabe, M.; Ichikawa, T.; Kobayashi, T.; Yano, R.; Kumanishi, T. Distribution of prepro-nociceptin/orphanin FQ mRNA and its receptor mRNA in developing and adult mouse central nervous systems. J. Comp. Neurol. 1998, 399, 139-151.
116. Neal, C. R., Jr.; Mansour, A.; Reinscheid, R.; Nothacker, H. P.; Civelli, O.; Watson, S. J., Jr. Localization of orphanin FQ (nociceptin) peptide and messenger RNA in the central nervous system of the rat. J. Comp. Neurol. 1999, 406, 503-547.
117. Courteix, C.; Coudore-Civiale, M. A.; Privat, A. M.; Pelissier, T.; Eschalier, A.; Fialip, J. Evidence for an exclusive antinociceptive effect of nociceptin/orphanin FQ, an endogenous ligand for the ORL1 receptor, in two animal models of neuropathic pain. Pain 2004, 110, 236-245.
118. Cremeans, C. M.; Gruley, E.; Kyle, D. J.; Ko, M. C. Roles of mu-opioid receptors and nociceptin/orphanin FQ peptide receptors in buprenorphineinduced physiological responses in primates. J. Pharmacol. Exp. Ther. 2012, 343, 72-81.
119. Cowan, A.; Lewis, J. W.; Macfarlane, I. R. Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br. J. Pharmacol. 1977, 60, 537-545.
120. Huang, P.; Kehner, G. B.; Cowan, A.; Liu-Chen, L. Y. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J. Pharmacol. Exp. Ther. 2001, 297, 688-695.
121. Clark, M. J.; Furman, C. A.; Gilson, T. D.; Traynor, J. R. Comparison of the relative efficacy and potency of mu-opioid agonists to activate Galpha(i/ o) proteins containing a pertussis toxin-insensitive mutation. J. Pharmacol. Exp. Ther. 2006, 317, 858-864.
122. Lutfy, K.; Eitan, S.; Bryant, C. D.; Yang, Y. C.; Saliminejad, N.; Walwyn, W.; Kieffer, B. L.; Takeshima, H.; Carroll, F. I.; Maidment, N. T.; Evans, C. J. Buprenorphine-induced antinociception is mediated by mu-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors. J. Neurosci. 2003, 23, 10331-10337.
123. Khroyan, T. V.; Polgar, W. E.; Jiang, F.; Zaveri, N. T.; Toll, L. Nociceptin/ orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin/orphanin FQ/mu-opioid receptor agonists. J. Pharmacol. Exp. Ther. 2009, 331, 946-953.
124. Ding, Z.; Raffa, R. B. Identification of an additional supraspinal component to the analgesic mechanism of action of buprenorphine. Br. J. Pharmacol. 2009, 157, 831-843.
125. Spagnolo, B.; Calo, G.; Polgar, W. E.; Jiang, F.; Olsen, C. M.; Berzetei-Gurske, I.; Khroyan, T. V.; Husbands, S. M.; Lewis, J. W.; Toll, L.; Zaveri, N. T. Activities of mixed NOP and mu-opioid receptor ligands. Br. J. Pharmacol. 2008, 153, 609-619.
126. Toll, L.; Khroyan, T. V.; Polgar, W. E.; Jiang, F.; Olsen, C.; Zaveri, N. T. Comparison of the antinociceptive and antirewarding profiles of novel bifunctional nociceptin receptor/mu-opioid receptor ligands: implications for therapeutic applications. J. Pharmacol. Exp. Ther. 2009, 331, 954-964.
127. Khroyan, T. V.; Polgar, W. E.; Orduna, J.; Montenegro, J.; Jiang, F.; Zaveri, N. T.; Toll, L. Differential effects of nociceptin/orphanin FQ (NOP) receptor agonists in acute versus chronic pain: studies with bifunctional NOP/mu receptor agonists in the sciatic nerve ligation chronic pain model in mice. J. Pharmacol. Exp. Ther. 2011, 339, 687-693.
128. Sukhtankar, D. S.; Zaks, M. E.; Zaveri, N. T.; Husbands, S. M.; Ko, M. C. Effects of spinally administered bifunctional MOP/NOP ligands in mouse models of neuropathic and inflammatory pain Society for Neuroscience 2012 - Abstract; 2012.
129. Khroyan, T. V.; Polgar, W. E.; Cami-Kobeci, G.; Husbands, S. M.; Zaveri, N. T.; Toll, L. The first universal opioid ligand, (2S)-2- [(5R,6R,7R,14S)-N- cyclopropylmethyl-4,5-epoxy-6,14-ethano-3-hydroxy- 6-meth oxymorphinan-7-yl]-3, 3-dimethylpentan-2-ol (BU08028): characterization of the in vitro profile and in vivo behavioral effects in mouse models of acute pain and cocaine-induced reward. J. Pharmacol. Exp. Ther. 2011, 336, 952-961.
130. Khroyan, T. V.; Zaveri, N. T.; Polgar, W. E.; Orduna, J.; Olsen, C.; Jiang, F.; Toll, L. SR 16435 [1-(1-(bicyclo[3.3.1]nonan-9-yl)piperidin-4-yl) indolin- 2-one], a novel mixed nociceptin/orphanin FQ/mu-opioid receptor partial agonist: analgesic and rewarding properties in mice. J. Pharmacol. Exp. Ther. 2007, 320, 934-943.
131. Molinari, S.; Camarda, V.; Rizzi, A.; Marzola, G.; Salvadori, S.; Marzola, E.; Molinari, P.; McDonald, J.; Ko, M. C.; Lambert, D. G.; Calo, G.; Guerrini, R. [Dmt(1) ]N/OFQ(1-13)-NH(2) , a potent nociceptin/orphanin FQ and opioid receptor universal agonist. Br. J. Pharmacol. 2012.
132. Wu, H.; Wacker, D.; Mileni, M.; Katritch, V.; Han, G. W.; Vardy, E.; Liu, W.; Thompson, A. A.; Huang, X. P.; Carroll, F. I.; Mascarella, S. W.; Westkaemper, R. B.; Mosier, P. D.; Roth, B. L.; Cherezov, V.; Stevens, R. C. Structure of the human kappa-opioid receptor in complex with JDTic. Nature 2012, 485, 327-332.
133. Manglik, A.; Kruse, A. C.; Kobilka, T. S.; Thian, F. S.; Mathiesen, J. M.; Sunahara, R. K.; Pardo, L.; Weis, W. I.; Kobilka, B. K.; Granier, S. Crystal structure of the micro-opioid receptor bound to a morphinan antagonist. Nature 2012, 485, 321-326.